Noom Launches At-Home Biomarker Test Kit to Track GLP-1 and Metabolic Health — Noom Inc.

Event summary

Noom launched an at-home Biomarkers Test Kit on May 27, 2026, enabling members to track 17 clinically significant biomarkers, including HbA1c, ApoB, and Lp(a).
The kit costs $125 and is available to all Noom members in the U.S., with results delivered within a week via the Noom app.
Early data from Noom's Proactive Health program revealed significant undetected metabolic risk, even among individuals with a healthy BMI.
The test includes Lp(a) testing, a genetic cardiovascular risk factor recommended by the American College of Cardiology and the American Heart Association.

The big picture

Noom's at-home biomarker test kit positions the company at the intersection of digital health and preventive care, addressing a significant gap in early intervention for metabolic and cardiovascular risks. The launch aligns with broader industry trends toward consumer-driven health diagnostics and personalized medicine, potentially expanding Noom's role in the preventive care ecosystem. The kit's affordability and ease of use could drive wider adoption, but success will depend on Noom's ability to integrate testing with its existing programs and maintain regulatory compliance.

What we're watching

Market Adoption: The pace at which Noom can drive adoption of its at-home biomarker test kit among members and whether it can compete with other at-home testing providers.
Clinical Integration: How effectively Noom can integrate biomarker testing with its existing behavior change and medication programs to improve health outcomes.
Regulatory Compliance: Whether Noom can maintain compliance with regulatory guidelines as it expands its diagnostic capabilities and partners with healthcare providers.